<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018962</url>
  </required_header>
  <id_info>
    <org_study_id>2017/2046</org_study_id>
    <nct_id>NCT05018962</nct_id>
  </id_info>
  <brief_title>Recurrent Stenoses in Arteriovenous Fistula (AVF) for Dialysis Access: CuttIng ballooN angioplaSTy Combined wITh Paclitaxel drUg coaTed Balloon Angioplasty, an observatIONal Clinical Study</brief_title>
  <acronym>INSTITUTION</acronym>
  <official_title>Recurrent Stenoses in Arteriovenous Fistula (AVF) for Dialysis Access: CuttIng ballooN angioplaSTy Combined wITh Paclitaxel drUg coaTed Balloon Angioplasty, an observatIONal Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if cutting balloon angioplasty combined with DEB angioplasty provides a higher&#xD;
      primary patency after treatment of recurrent stenoses compared with cutting balloon&#xD;
      angioplasty or angioplasty using DEB alone in the venous outflow AVFs. For cutting balloon&#xD;
      angioplasty in venous stenosis, the primary patency after 12 months is 55-60% (9,16) and in&#xD;
      recurrent stenoses up to 48%(10).&#xD;
&#xD;
      We hypothesise that DEB angioplasty after cutting balloon angioplasty leads to improved&#xD;
      primary patency at 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2017</start_date>
  <completion_date type="Actual">March 18, 2020</completion_date>
  <primary_completion_date type="Actual">April 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion primary patency</measure>
    <time_frame>1 year</time_frame>
    <description>Target lesion primary patency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circuit primary patency</measure>
    <time_frame>1 year</time_frame>
    <description>Circuit primary patency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion primary assisted patency</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Dialysis Access Malfunction</condition>
  <arm_group>
    <arm_group_label>Cutting balloon followed by paclitaxel coated balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cutting balloon followed by paclitaxel coated balloon</intervention_name>
    <description>Cutting balloon followed by paclitaxel coated balloon</description>
    <arm_group_label>Cutting balloon followed by paclitaxel coated balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recurrent stenoses (within 1 year after angioplasty) in the venous outflow of AVFs for&#xD;
             dialysis access (&gt; 0.5cm from AV anastomosis up to cephalic arch)&#xD;
&#xD;
          -  Successful guidewire crossing of target lesion&#xD;
&#xD;
          -  ≥ 21 years old&#xD;
&#xD;
          -  Informed and valid consent given.&#xD;
&#xD;
          -  Patient willing and able to return for follow up .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Thrombosed AVFs or occlusions in the access circuit&#xD;
&#xD;
          2. Significant cephalic arch (central perpendicular portion of the cephalic vein) or&#xD;
             central vein stenoses.&#xD;
&#xD;
          3. &gt; 3 stenosed segments (lesions are considered separate if they are separated by at&#xD;
             least 2 cm normal vessel.)&#xD;
&#xD;
          4. Only potential target lesion located in cephalic arch, central veins or anastomotic&#xD;
             lesions.&#xD;
&#xD;
          5. Only de novo stenoses identifiable as target lesion.&#xD;
&#xD;
          6. Target lesion resistant to cutting balloon angioplasty (&gt;30% residual stenosis with&#xD;
             incomplete effacement of the lesion during cutting balloon angioplasty)&#xD;
&#xD;
          7. Target lesion not treatable with the available sizes of cutting balloon (4-7mm) and&#xD;
             drug eluting balloon (up to 8mm) so native reference vessel &lt;3 mm or need for DEB&#xD;
             balloon &gt;8mm.&#xD;
&#xD;
          8. Lesion in excess of 8 cm&#xD;
&#xD;
          9. Unable to take dual antiplatelet therapy for 1 month and/or aspirin for 6 months&#xD;
&#xD;
         10. Coagulopathy (PT or PTT &gt;1.5 times the median of normal range) or thrombocytopenia&#xD;
             (platelet count &lt;50,000 /μL) that cannot be managed adequately with periprocedural&#xD;
             transfusion.&#xD;
&#xD;
         11. Patient on Warfarin.&#xD;
&#xD;
         12. Known allergy to iodinated contrast that cannot be managed adequately with&#xD;
             pre-procedure medication.&#xD;
&#xD;
         13. Allergy / contraindication to dual anti-platelet therapy (aspirin and clopidogrel or&#xD;
             ticlopidine) or paclitaxel.&#xD;
&#xD;
         14. Acute infection over proposed puncture site.&#xD;
&#xD;
         15. Women who are breastfeeding, pregnant or planning on becoming pregnant during study.&#xD;
&#xD;
         16. Participant with medical conditions, which in the opinion of the investigator may&#xD;
             cause non-compliance with protocol.&#xD;
&#xD;
         17. Currently participating in an investigational drug, biologic or device trial that may&#xD;
             have an impact on the dialysis access or previous enrolment in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paclitaxel coated balloon</keyword>
  <keyword>Cutting balloon</keyword>
  <keyword>Recurrent stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

